Affiliation:
1. Infectious Diseases Research Laboratory, Mayo Clinic, Rochester, Minnesota 55905.
Abstract
Results of in vitro time-kill synergy studies using subinhibitory, inhibitory, or suprainhibitory concentrations of bactericidal agents were compared with treatment outcomes of experimental infective endocarditis due to a methicillin-susceptible strain of Staphylococcus aureus. For rifampin-cephalosporin combinations, in vitro synergy testing using recommended fractions of the MIC failed to predict antagonism in vivo while concentrations above the MIC corresponded with antagonism in vivo.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference22 articles.
1. American Society for Microbiology. 1993. Instructions to authors. Antimicrob. Agents Chemother. 37:i-xiii.
2. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile;Bartoloni A.;J. Antimicrob. Chemother.,1990
3. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations;Bayer A. S.;J. Infect. Dis.,1985
4. Eliopoulos G. M. and R C. Moellering Jr. 1991. Antimicrobial combinations p. 432-492. In V. Lorian (ed.) Antibiotics in laboratory medicine 3rd ed. Williams & Wilkins Co. Baltimore.
5. Garrison P. and L. Freedman. 1970. Experimental endocarditis. NOTES 2193
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献